Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply
N Engl J Med
.
2022 Feb 17;386(7):e17.
doi: 10.1056/NEJMc2114590.
Authors
Juan P Frías
1
,
Laura Fernández Landó
2
,
Katelyn Brown
2
Affiliations
1
National Research Institute, Los Angeles, CA juan.frias@nritrials.com.
2
Eli Lilly, Indianapolis, IN.
PMID:
35172067
DOI:
10.1056/NEJMc2114590
No abstract available
Publication types
Letter
Comment
MeSH terms
Diabetes Mellitus, Type 2* / drug therapy
Gastric Inhibitory Polypeptide
Glucagon-Like Peptides / adverse effects
Humans
Substances
semaglutide
Gastric Inhibitory Polypeptide
Glucagon-Like Peptides
tirzepatide